摘要
The recognition of the important role of cancer immunity in tumors has led to the introduction of immunotherapeutic strategies. Most of the immunomodulatory approaches currently being developed engage the adaptive immune system. The clinical approval of checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy has led to considerable success in treating hematologic malignancies.1,2,3,4 However, for the majority of patients with solid tumors, little or no progress has been seen. The efficacy of immunotherapies is limited by the complexities of a diverse set of immune cells and interactions between tumor cells and all other cells in the local microenvironment of solid tumors. A large proportion of immune cells in and around solid tumors derive from the innate arm of the immune system, and using these innate cells against tumors offers an alternative immunotherapeutic option, while current strategies mainly focus on the adaptive arm of the immune system.5 In a recent issue of Cell research, Lv et al.6 discovered that Mn2+ played a critical role in the innate immune sensing of tumors, as Mn-insufficient mice poorly controlled tumor growth and metastasis. Mechanistically, Mn2+ promoted dendritic cell (DC) and macrophage maturation and tumor-specific antigen presentation, augmented CD8+ T-cell differentiation and activation and NK cell activation, and increased memory CD8+ T cells in a cyclic-AMP synthase (cGAS)-stimulator of interferon genes (STING)-dependent manner, uncovering a critical role of Mn in bridging innate and adaptive immunity for tumor surveillance.
基金
supported by funds from the National Natural Science Foundation of China(Nos.31991171,81830002,and 31870873 to W.D.H.).
